175 related articles for article (PubMed ID: 26835885)
21. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
[TBL] [Abstract][Full Text] [Related]
22. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Konishi T; Horie H; Ikeuchi H; Eshima K; Muto T
Clin Transl Oncol; 2011 Jun; 13(6):419-25. PubMed ID: 21680303
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
Mirakhorli M; Rahman SA; Abdullah S; Vakili M; Rozafzon R; Khoshzaban A
Mol Med Rep; 2013 Feb; 7(2):613-7. PubMed ID: 23232902
[TBL] [Abstract][Full Text] [Related]
24. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
25. Folate pathway genes linked to mitochondrial biogenesis and respiration are associated with outcome of patients with stage III colorectal cancer.
Odin E; Sondén A; Carlsson G; Gustavsson B; Wettergren Y
Tumour Biol; 2019 Jun; 41(6):1010428319846231. PubMed ID: 31223065
[TBL] [Abstract][Full Text] [Related]
26. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Schirripa M; Loupakis F; Cao S; Zhang W; Yang D; Ning Y; Berger MD; Miyamoto Y; Suenaga M; Iqubal S; Barzi A; Cremolini C; Falcone A; Battaglin F; Salvatore L; Borelli B; Helentjaris TG; Lenz HJ
Cancer; 2017 Nov; 123(22):4506-4514. PubMed ID: 28708932
[TBL] [Abstract][Full Text] [Related]
27. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
Zhang W; Stoehlmacher J; Park DJ; Yang D; Borchard E; Gil J; Tsao-Wei DD; Yun J; Gordon M; Press OA; Rhodes K; Groshen S; Lenz HJ
Clin Colorectal Cancer; 2005 Jul; 5(2):124-31. PubMed ID: 16098254
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
29. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
Madbouly KM; Hussein AM; Zeid A
Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
[TBL] [Abstract][Full Text] [Related]
30. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Lin PC; Lin HH; Lin JK; Lin CC; Yang SH; Li AF; Chen WS; Chang SC
Int J Biol Markers; 2013 Jun; 28(2):182-6. PubMed ID: 23558935
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Kim DY; Paek TY; Oh SY; Kim YB; Lee JH; Lee MY; Choi ZS; Suh KW
J Surg Oncol; 2014 Mar; 109(3):250-4. PubMed ID: 24318863
[TBL] [Abstract][Full Text] [Related]
32. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T
Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634
[TBL] [Abstract][Full Text] [Related]
34. Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
Catalano C; da Silva Filho MI; Jiraskova K; Vymetalkova V; Levy M; Liska V; Vycital O; Naccarati A; Vodickova L; Hemminki K; Vodicka P; Weber ANR; Försti A
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):838-842. PubMed ID: 29762254
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin in the treatment of colorectal cancer.
Kim GP; Erlichman C
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
[TBL] [Abstract][Full Text] [Related]
36. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Lin L; Zhang Z; Zhang W; Wang L; Wang J
Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
[TBL] [Abstract][Full Text] [Related]
37. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
[TBL] [Abstract][Full Text] [Related]
39. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Vincenzi B; Santini D; Perrone G; Graziano F; Loupakis F; Schiavon G; Frezza AM; Ruzzo AM; Rizzo S; Crucitti P; Galluzzo S; Zoccoli A; Rabitti C; Muda AO; Russo A; Falcone A; Tonini G
J Cell Physiol; 2012 Mar; 227(3):927-33. PubMed ID: 21503888
[TBL] [Abstract][Full Text] [Related]
40. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
